DKFZ 39 records found  1 - 10nextend  jump to record: Search took 0.00 seconds. 
DBCoverage [DKFZ-2023-00098] Journal Article
; ; ; et al
Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation.
While major advances have been made in improving the quality of life and survival of children with most forms of medulloblastoma (MB), those with MYC-driven tumors (Grp3-MB) still suffer significant morbidity and mortality. There is an urgent need to explore multimodal therapeutic regimens which are effective and safe for children. [...]
[DKFZ-2022-02555] Journal Article
; ; ; et al
CD155 is a putative therapeutic target in medulloblastoma.
Medulloblastoma is the most common pediatric malignant brain tumor, consisting of four molecular subgroups (WNT, SHH, Group 3, Group 4) and 12 subtypes. Expression of the cell surface poliovirus receptor (PVR), CD155, is necessary for entry of the viral immunotherapeutic agent, PVSRIPO, a polio:rhinovirus chimera. [...]
DBCoverage [DKFZ-2022-01467] Journal Article
; ; ; et al
The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors.
Most lncRNAs display species-specific expression patterns suggesting that animal models of cancer may only incompletely recapitulate the regulatory crosstalk between lncRNAs and oncogenic pathways in humans. Among these pathways, Sonic Hedgehog (SHH) signaling is aberrantly activated in several human cancer entities. [...]
[DKFZ-2022-01081] Journal Article
; ; ; et al
Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis.
Neuro-Oncology 24(9), 1509-1523 () [10.1093/neuonc/noac068]  GO
Intratumoral heterogeneity is crucially involved in metastasis, resistance to therapy and cancer relapse. Amplifications of the proto-oncogene MYC display notable heterogeneity at the single-cell level and are associated with a particularly dismal prognosis in high-risk medulloblastomas. [...]
DBCoverage [DKFZ-2022-00672] Journal Article
; ; ; et al
EIF4EBP1 is transcriptionally upregulated by MYCN and associates with poor prognosis in neuroblastoma.
Neuroblastoma (NB) accounts for 15% of cancer-related deaths in childhood despite considerable therapeutic improvements. While several risk factors, including MYCN amplification and alterations in RAS and p53 pathway genes, have been defined in NB, the clinical outcome is very variable and difficult to predict. [...]
[DKFZ-2022-00559] Journal Article
; ; ; et al
Progenitor cells derived from gene-engineered human induced pluripotent stem cells as synthetic cancer cell alternatives for in vitro pharmacology.
Limitations in genetic stability and recapitulating accurate physiological disease properties challenge the utility of patient-derived (PD) cancer models for reproducible and translational research. We have genetically engineered a portfolio of isogenic human induced pluripotent stem cells (hiPSCs) with different pan-cancer relevant oncoprotein signatures followed by differentiation into lineage-committed progenitor cells. [...]

DKFZ : 39 records found   1 - 10nextend  jump to record:
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.